Hydrocortisone Medo (Hydrocortisone)

Hydrocortisone Medo is indicated for several clinical situations where glucocorticoid activity is required.

• Treatment of primary or secondary adrenal insufficiency (Addison’s disease) to replace cortisol.
• Management of acute shock states, including septic, anaphylactic, or other severe circulatory collapse.
• Control of severe inflammatory reactions such as asthma exacerbations, severe dermatitis, or rheumatic flare-ups.
• Rapid mitigation of life‑threatening allergic responses, including angioedema and bronchospasm.
• Adjunct therapy in postoperative patients to reduce inflammation and support hemodynamic stability.

• Hydrocortisone Medo acts as an agonist at intracellular glucocorticoid receptors. After crossing cell membranes, the drug binds to the receptor complex, translocates to the nucleus, and modulates gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and reduced expression of adhesion molecules, collectively producing anti‑inflammatory, immunosuppressive, and metabolic effects that mimic endogenous cortisol and physiological stress responses.

Adverse reactions to Hydrocortisone Medo may vary in frequency and severity.

Common

• Transient increase in blood glucose levels, often noted as mild hyperglycemia.
• Mild electrolyte changes, typically mild sodium retention or potassium loss.
• Local discomfort, pain, or erythema at the intramuscular or intravenous injection site.
• Headache, light‑headedness, or occasional dizziness shortly after administration.

Serious

• Marked hyperglycemia that may precipitate diabetic ketoacidosis in susceptible patients.
• Significant elevation of blood pressure or fluid retention leading to pulmonary edema.
• Acute adrenal insufficiency when the drug is stopped abruptly without tapering.
• Severe hypersensitivity reactions such as widespread rash, urticaria, or life‑threatening anaphylaxis.

Before prescribing Hydrocortisone Medo, clinicians should evaluate several safety considerations.

• Assess for existing infections, as glucocorticoids can mask signs and worsen outcomes.
• Review patient history for diabetes, hypertension, or osteoporosis, which may be aggravated.
• Use the lowest effective dose for the shortest duration to limit systemic effects.
• Monitor blood glucose, electrolytes, and blood pressure regularly during therapy.
• Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal crisis.
• Consider potential effects on wound healing and surgical recovery.
• Evaluate pregnancy and lactation status, recognizing limited safety data.

Hydrocortisone Medo can interact with other medicines, altering efficacy or safety.

Avoid

• Concomitant use with strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine may markedly lower hydrocortisone concentrations, reducing therapeutic effect.
• Co‑administration with additional systemic glucocorticoids (e.g., prednisone, dexamethasone) can potentiate immunosuppression, hyperglycemia, and fluid retention.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration or bleeding when combined with glucocorticoids.
• Anticoagulants, particularly warfarin, may have an enhanced anticoagulant response, necessitating more frequent INR checks.
• Live or attenuated vaccines may be less effective or cause disease due to immunosuppression; timing should be coordinated.